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l
Samevattend, kan AMC du be kou word as 'n uit-
gebreide kongenitale simmetriese gewrigsaandoening wat
die eindresultaat van meer as een patologie e proses
verteenwoordig. Baie gevalle wat egter as AMC gerap-
porteer is, het feitlik net een of twee gewrigte met fieksie-
deformiteite gehad, en stem nie ooreen met die kenmerken-
de kliniese beeld wat oorspronklik deur Stern in 1925 be-
skrywe is en hierbo genoem is nie.' By kenmerkende gevaIle,
in die afwesigheid van 'n ander bekende spier- of neurale
toestand, moet 'n noukeurige stamboom-analise gedoen
word. VoorIigting vir geval 2 het op outosomale resessiewe
basis geskied, maar by geval 1, waar die ouerpaar reeds
5 kinders sonder AMC het is die oorerwing as dominant
beskou. Hierdie geval kon moontlik 'n nuwe mutasie
verteenwoordig het. Die moeder i egter gesteriliseer en
dus was die informasie dat daar geen herhalingsrisiko was
Die, slegs 'n interessante feit.
Ons wil graag professor M. P. Keet bedank vir toestemming
en fasiliteite om die pasiente na te gaan.
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Neurochemical Aspects of Porphyria
STUDIES ON THE POSSIBLE NEUROTOXICITY OF
DELTA-AMINOLAEVULINIC ACID
B. C. SHANLEY, A. C. NEETIILING, V. A. PERCY, M. CARSTENS
SUMMARY
It has been proposed that delta-aminolaevulinic acid (ALA),
which is overproduced in the inherited hepatic porphyrias,
may be responsible for the neurological manifestations
of the acute attacks seen in these disorders. Studies were
conducted in rats to test the neurotoxicity of ALA. It was
found that, after intraperitoneal or subcutaneous in-
jections, ALA is rapidly eliminated via the kidneys. In
nephrectomised animals sustained elevation of blood ALA
concentration was demonstrated, but despite this, brain
uptake was extremely low. Experiments on incorporation
of [4 -"C] - ALA into brain haem yielded similar
information. After intraventricular injection of [4-"C]
- ALA, signifIcant uptake by brain tissue occurred. The
subsequent disappearance of ALA was moderately rapid
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and was virtually complete within 24 hours. Uptake of
[4 - "C] - ALA was apparently significantly greater in
the hypothalamus than in other brain areas. The subcellular
distribution of radioactivity did not reveal any preferential
uptake by nerve endings. Intraventricular injection of
unlabelled ALA revealed definite but transitory neurotoxic
effects in doses of 3 -micromoles and greater. These include
involuntary movements and ataxia. No effect of ALA
administration on brain protein synthesis could be demon-
strated. It is concluded that ALA does have effects on
the nervous system in vivo, but the significance of these
effects in relation to the pathogenesis of the neurological
manifestations of acute porphyria is questionable.
S. Afr. Md J., ..." 576 (1975).
The clinical manifestations of the acute attack in the
inherited hepatic porphyrias are generally recognised as
being largely neurological or neuropsychiatric in nattrre.
Virtually nothing is known, however, of the nattrre of
the UIlderIying disturbance.
Various hypotheses have been proposed from time to
time. Among these is the idea that porphyrin precursors
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which are overproduced in all these disorders may be
neurotoxic. Earlier tudies by Goldberg and Rimington'
and Jarrett eT al.' suggested that both delta-aminolaevulinic
acid (ALA) and porphobilinogen (PBG) were innocuous
substances. More recently, this view has been questioned.
Feldman and co-workers3 have shown that ALA and PBG
can cause presynaptic inhibition of neurotransmitter release.
Becker et al. have found that ALA can inhibit a+K+-
dependent ATPase in brain' and that both ALA and
PBG have an inhibitory effect on monosynaptic reflex
activity in the isolated frog spinal cord.' However, none
of this recent evidence can be accepted as conclusive, since
it relates only to in viTro effects of these porphyrin
precursors on neural tissue.
An evaluation of the possible neurotoxicity of ALA and
PBG obviously necessitates detailed information on their
effects and behaviour in vivo. These data are largely un-
available. The present study was undertaken to examine
the consequences of administering ALA peripheraIJy, or
directly into the nervous system, in experimental animals.
MATERIAL AND METHODS
The animals employed were young adult female albino
rats weighing 150 - 250 g. In each experiment the test and
control animals were matched for age and weight. Animals
were sacrificed by decapitation at the times indicated in
the individual experiments. Tissues were promptly removed,
rapidly frozen and kept at -20°C until analysis.
ALA, obtained from Sigma Chemical Co., USA, or
[4 - HC] - ALA was administered by the intraperitoneal,
subcutaneous or intraventricular routes as indicated below.
Intraventricular injections were carried out under light
ether anaesthesia according to the method of oble eT al.'
Solutions of unlabelJed ALA for intraventricular injection
were adjusted as near as possible to pH 7,4 prior to
administration.
Radiochemicals were obtained from the Radiochemical
Centre, Amersham, UK. The purity of [4- HC1- ALA
(SA 53 mCi/ mmoI) was checked chromatographically and
found to be greater than 900 0. Other reagents employed
were all of analytical grade.
Tissues were homogenised in O,lM trichloroacetic acid
(TCA) and ALA and PBG were then determined in the
clear supematant after centrifugation according to the
method of Marver et al.' In the study of [4-HC]-ALA
uptake by the brain after intraventricular injection, the ven-
tricles were opened and thoroughly washed in physiological
saline before homogenisation of the ti sue in O,IM TCA.
Total radioactivity was determined in a Packard Tricarb
liquid scintillation pectrometer model 3385 on aliquots
of the clear supernatant preparation after centrifugation.
[4-"Cl-ALA was determined in the supernatant olu-
tions by column chromatography according to Ebert et al."
followed by pyrrole formation, extraction of the pyrrole
with ethyl acetate' and determination of radioactivity in
this extract. Haem was isolated with the aid of carrier
in the form of washed erythrocytes according to Labbe
and ishida.'o Samples were prepared for counting by
combu tion in a Packard ample oxidiser. Incorporation
of [35S1- methionine and L-[ -HC)-Iysine into brain
protein wa determined by the method of Agrawal et al."
Regional dissection of the brain was carried out according
to Glowinski and Iver en." The technique of ubceliular
fractionation was essentially as described by Marchbanks
and Whittaker. 13
RESULTS
Brain ALA Uptake in ormal Rats
Previous preliminary tudie uggested that ALA ad-
ministered peripherally did not readily enter the nervous
system.H This was justifiably criticised on the grounds
that blood levels were not determined." Accordingly, the
first step was to examine concentrations of ALA in blood,
brain and liver 4 hour after a single intraperitoneal
injection of ALA.
Despite a dose as high as 500 mg/kg, ALA was un-
detectable in blood, liver and brain in these animals.
nfortunately, the urinary excretion of ALA was not
measured in this experiment but there was little doubt
that the injected ALA must have been rapidly eliminated
by the kidneys. Therefore, it was decided to repeat the
experiment in nephrectomised animal .
Brain ALA Uptake in Nephrectomised Rats
Bilateral nephrectomy was performed under ether
anaesthesia on young adult rat . ALA was injected ub-
cutaneously (in order to avoid the intraperitoneal route)
on the subsequent day. All the animal were id good
condition at the time of the injection. The results are shown
in Table l.
Substantial concentrations of ALA were found 4 hours
after injection in blood and liver but not in brain in these
animals. Initially, as indicated in the table, the ALA
concentration in brain was found to be below the limit
of detection. When the experiment was repeated, u ing
the whole brain for analysis, the ALA level was found
to be 74 nanomoles/g (SD 14) in association with a
blood concentration of 0,96 mM (SD 0,28). In the brain,
therefore, the concentration of ALA was less than 10%
of that found in the liver and the blood. The blood
concentration achieved after 500 mg/ kg was well in excess
of what might be expected in patients with acute por-
phyria." To assess the effect of barbiturate on the entry
of ALA into the brain the experiment was repeated, with
the administration of sodium phenobarbitone (60 mg/kg)
together with ALA. 0 significant effect wa noted.
Incorporation of Radioactivity from [4 - 1'1C]
-ALA into Liver and Brain Haem in ormal Rats
Incorporation of [4- HC]-ALA into liver and brain
haem ill vivo was compared with results obtained by
incubating these tissues in viTro with [4-"C]- ALA.
The do e of [4-"Cl-ALA wa 0,1 fLCi/g body weight.
Ti sue were homogenised in 9 volumes of aline with
washed erythrocytes (in vivo experiment) or 10 mM tris-
aline buffer, pH 7,4 (in vitro experiment). Incubation
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TABLE I. MEAN TISSUE CONCENTRATIONS OF ALA AND PBG IN NEPHRECTOMISED RATS 4 HOURS AFTER SUB-
CUTANEOUS INIECTION OF ALA
Dose of ALA
ALA Blood Brain Liver
(mg/kg) (mmol/I) (nmoles/g) (nmoles/g)
0 NO NO NO
250 0,25 NO 908
500 0,54 NO 1164
PBG
Blood Brain Liver
(mmol/I) (nmoles/g) (nmoles/g)
NO NO NO
ND ND 138
ND ND 159
ND = not detectable.
Each result represents the mean of 5 observations.
mixtures comprised homogenate with added [4- H C]
-ALA (0,25 jiCi/rnl) and ferric chloride (0,6 mM).
Incubations were carried out aerobically with shaking at
37°C for 1 hour. The results are shown in Table H.
TABLE Ill. UPTAKE BY BRAIN AND DISAPPEARANCE OF
[4-"C]-ALA AFTER INTRAVENTRICULAR INJECTION
OF 5 jiCi
Percentage of original dose in brain
TABLE 11. COMPARISON OF THE INCORPORATION OF
[4-"C]-ALA INTO LIVER AND BRAIN HAEM IN VIVO
AND IN VITRO
1> Mean of 5 observations.
Total radioactivity Radioactivity extractable
as ALA
Experiment
Liver
(dpm/4 mg)
Radioactivity of haem
Brain Liver : brain
(dpm/4 mg) ratio
Time after
injection
(hours)
2
4
24
Mean*
23,2
11,6
0,7
SD
6,6
5,8
0,2
Mean*
9,1
3,5
0,05
SD
1,8
0,6
0,01
Distribution and Metabolism of [4 - 14C] - ALA
Following Intraventricular Injection
The liver : brain ratio in the in vitro experiment was
very much lower than that obtained in vivo. It must be
pointed out that the conditions of incubation which were
used in the in vitro experiment may not have been ideal
for maximal incorporation of labelled ALA into haem,
either in liver or in brain. Nevertheless, the values obtained
would appear to confirm the finding in the preceding
experiment that the 'blood-brain barrier' in the normal rat
is relatively impermeable to ALA.
The fact that significant amounts of ALA cannot be
detected in brain following acute elevation of the blood
concentration of ALA, does not rule out the possibility
that this substance might gradually accumulate in the
nervous system in patients with acute porphyria, until a
toxic level is reached. Accordingly, it was decided to
experiment with direct introduction of ALA into the
nervous system.
Table III shows the uptake and disappearance of [4-
"C] - ALA from rat brain at intervals after intraventricular
injection of 5 jiCi. Two hours after injection approximately
23% of the administered radioactivity had been taken up
by the brain, but less than half of this was recoverable as
ALA. After 4 hours the total radioactivity present had
halved and ALA accounted for less than one-third. Twenty-
four hours after injection only 0,7% of the administered
dose was still present and ALA constituted less than 10%.
4 See text for details.
Radioactivity
(dpm/mg tissue)
Mean* SD
1 236 184
994 306
3750 963
1277 380
819 104
1 190 282
Tn the preceding experiments tracer amounts of [4- H C]
- ALA were administered intraventricularIy. The next
The regional distribution of radioactivity 2 hours after
intraventricular injection of [4- H C]-ALA is shown in
Table IV. A significantly higher concentration was found
in the hypothalamus compared with other brain regions.
.. Mean of 5 observations.
TABLE IV. REGIONAL DISTRIBUTION OF RADIOACTIVITY
IN BRAIN 2 HOURS AFTER INTRAVENTRICULAR INJECTION
OF [4- 14C]-ALA (5 [LCi)
Brain region
Cerebellum ...
Pons
Hypothalamus
Midbrain
Striatum
Cortex
It was also of interest to know whether ALA is con-
centrated in any particular subcellular fraction following
uptake into the brain. Table V shows the subcellular
distribution of radioactivity in rat brain 2 hours after
intraventricular injection of [4- H C]-ALA. Most of the
radioactivity was found in the soluble fraction and there
was no evidence of a peak in the synaptosomal or
'nerve ending' fraction.
Effect of Inn-aventricular Injection of ALA on
Behaviour in Rats
657
36
271
721
178 X 10'
26 X 10'
In viYo*
In Yitro*
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TABLE V. SUBCELLULAR DISTRIBUTION OF RADIOACTIVITY
IN BRAIN 2 HOURS AFTER INTRAVENTRICULAR INJECTION
OF [4-"C]-ALA (5 flCi)
rence was found between normal animals and those treated
with ALA with regard to the incorporation of radioactivity
either into the free amino acid pool or into brain protein.
TABLE VI. INCORPORATION OF ["S]-METHIONINE INTO
BRAIN PROTEIN IN NEPHRECTOMISED RATS AFTER
SUBCUTANEOUS ADMINISTRATION OF ALA
Radioactivity
Mean* SD
Acid-soluble fraction
(dpmjmg brain)
Protein
(dpmjmg)
Mean· SD
378 59
290 13
340 36
1 952
1 9.0
1477
8762
8838
8850
Dose of ALA
(mgjkg)
o
250
500
Mean* SD
100,0
4,8 1,9
61,7 7,3
25,4 4,0
6,0 1,3
5,2 1,7
4,1 2,4
Percentage of total
radioactivity
* Mean of 5 observations.
Subcellular fraction
Whole homogenate
Nuclear pellet
Supernatant ...
Crude mitochondrial fraction
Myelin
Synaptosomes ...
Mitochondria
.. Mean of 5 observations.
'It Tissues of 5 animals pooled.
DISCUSSION
TABLE VII. INCORPORATION OF L· [U·'·C]-LYSINE INTO
BRAIN PROTEIN IN RATS AFTER INTRAVENTRICULAR
ADMINISTRATION OF ALA
No ALA
467
546
~64
455
366
523
Radioactivity of brain protein (dpmjmg)*
ALA 1 ALA 3
j-tmole fLmole
551 452
513 547
521 496
450 356
364 39'1
442 545
Brain region
Cereb<:lIum
Pons
Hypothalamu5
Midbrain
Striatum
Cortex
These studies clearly show that after intraperitoneal
or subcutaneous injection of ALA in the experimental
animal, this amino acid is rapidly eliminated via the
kidneys. In an attempt to simulate the situation in acute
porphyria, we administered ALA to nephrectomised animals
and were able to demonstrate that 4 hours after injection
of 500 mgj kg the mean blood level ranged from 0,54
to 0,96 mM in different experiments. This is considerably
higher than the blood concentration expected in porphyric
patients during acute attacks.'"
Despite this sustained elevation of ALA concentration
in the blood, uptake into the brain in the present study
was negligible in comparison with liver uptake of ALA.
Thi suggests that the blood-brain barrier, at least in the
normal animal, is relatively impermeable to ALA. Con-
sequently, if elevated blood levels of ALA in patients with
acute porphyria do lead to accumulation of this amino-
ketone in the nervous y tern, then either the blood-brain
barrier must be much more permeable to ALA under
these circumstances or, alternatively, ALA must slowly
accumulate in the nervous system when circulating blood
levels are chronically elevated.
step was to examine the effect of intraventricular injection
of larger amounts of unlabelled ALA. With a dose of
up to 2 micromoles delivered in 30 microlitres of buffered
solution (pH 7,4) no discernible gross behavioural effects
were noted. The animals recovered quite normally from
the anaesthetic and no untoward effects could be observed.
At higher dosages, however, definite effects were noted.
The animals took longer to recover from anaesthesia.
With doses of 3 and 5 flmoles 'jumping seizures' were
prominent during the recovery phase, i.e. the animals
made involuntary forward jumps during this time but
later (after approximately I hour) they appeared quite
normal. A few of the control animals also showed this
phenomenon, but to a much lesser extent. A dose of 10
flmoles did not produce these 'jumping seizures' but
ataxia was marked for several hours after recovery from
anaesthesia. In a group of smaller animals weighing about
130 g this dose proved uniformly fatal within minutes
after injection.
The solutions containing 5 or 10 flmolesj30 fll were
undoubtedly hypertonic, which raised the question as to
whether any of the observed effects might be attributable
to this reason. Hypertonic saline solutions (l,8% and 2,7~o
aCI) were, however, found to have no untoward effects
when injected intraventricularly.
Apart from possible direct effects of ALA on neural
tissue, the possibility was also considered that this amino
acid might be indirectly responsible for pathological
changes in the nervous system, e.g. through interference
with protein synthesis, as has been shown in experimental
hyperphenylalaninaemia."
Tables VI and VII show the incorporation of radio-
activity from ["5]-methionine and L- [U _HC] -lysine
respectively into the acid-soluble fraction and into protein
in rat brain after administration of ALA. In the
case of ["5] - methionine ALA was administered sub-
cutaneously and the animals were nephrectomised on the
preceding day. ]n the case of L -[U-HC]-lysine, ALA
was administered intraventricularly. 0 significant diffe-
Effect of ALA Administration on Brain Protein
Synthesis
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There is, of course, no reliable information available on
the concentration of ALA in the nervous system in acute
porphyria. What evidence is available suggests that plasma
concentrations may be ten times those found in the
cerebrospinal fluid." The possibility tbat barbiturates, which
are well known to be precipitating agents of acute attacks,
migbt enhance uptake of ALA into the nervous system,
was also examined in the present study. No significant
effect was found.
Kramer et al." have suggested that ALA may accumulate
in the nervous system in patients with acute porphyria and
subsequently interfere with nerve conduction. Our experi-
ments using intraventricular injection of [4- H C]-ALA
would seem to indicate that while ALA is readily taken
up from the cerebrospinal fluid into the brain, it is fairly
rapidly metabolised and removed. This process is virtually
complete in 24 hours. Therefore it is unlikely that ALA
slowly accumulates in neural tissue, either as a result of
uptake from the blood or as a result of endogenous
production in the nervous system.
The significance of the preferential uptake of radioactivity
by the hypothalamus following intraventricular adminis-
tration of [4- H C] - ALA is not at all clear. Unfortunately
the percentage of this radioactivity present in tbe hypo-
thalamus as ALA was not determined. Conceivably, if
ALA does gain access to the brain in significant amounts
in acute porphyria, the highest concentrations could be
expected in the hypothalamus. This in turn could possibly
underlie the presumed inappropriate secretion of anti-
diuretic hormone seen in acute porphyric patients with
hyponatraemia. However, this is highly speculative and
the central problem of whether or not ALA does reach
toxic levels in the nervous system in acute porphyria
remains.
Intraventricular administration of relatively large
amounts of ALA produced definite neurotoxic effects of
an immediate but transitory nature. These include involun-
tary movements, mainly of the hind limbs, and prolonged
ataxia. In small animals weighing about 130 g, 10 I'moles
of ALA was uniformly fatal within minutes, apparently
owing to respiratory failure. Animals which survived, on
the other hand, seemed to suffer no residual ill-effects
after 24 hours. There is no doubt, therefore, that ALA is
potentially neurotoxic if introduced into the nervous system
in sufficient concentration. Whether or not this could occur
in patients is, as indicated previously, highly debatable.
A further consideration is whether or not the types of
neurological effects noted in our experiments have any
relevance to the neurological lesions of acute purphyria.
Alterations in the free amino acid pool in the brain can
interfere with brain protein synthesis, as has been shown
III experimental hyperphenylalaninaemia." Studies were
done to test the possibility tbat ALA might conceivably
induce neurological damage via such a mechanism. How-
ever, no significant effect of elevated blood ALA concen-
tration or of intraventricular administration of ALA was
demonstrable.
In conclusion, the present study has shown that ALA
when introduced directly into the nervous system by intra-
ventricular injection can exert transitory neurotoxic effects.
Nevertheless, there are major objections to the hypothesis
that ALA is the neurotoxic factor in acute porphyria.
Chief among these is the finding that in experimental
animals there is a substantial blood-brain barrier to ALA
and the demonstration that ALA introduced by intra-
ventricular injection is relatively rapidly removed. It may
be that it is not ALA but rather some pyrrolic compound
which is the elusive factor. There are a number uf
possibilities which require examination. On the other hand,
the solution to the mystery may lie in a study of haem
biosynthesis in neural tissue. It is entirely plausible that
the metabolic lesion which is present in the liver in the
inherited hepatic porphyrias is also present in the neurons.
If this is so, it could be that acute attacks represent crises
of 'haem starvation' occasioned by various stresses on the
nerve cell, including drugs such as the barbiturates.
Studies on these possibilities are in progress.
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